Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Single Ascending Doses of BIIB063 in Healthy Volunteers

17. april 2017 oppdatert av: Biogen

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers. The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

29

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • West Yorkshire
      • Leeds, West Yorkshire, Storbritannia, LD2 9LH
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
  • Must have a body mass index between 18 and 30 kg/m2, inclusive.
  • Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.

Key Exclusion Criteria:

  • History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
  • History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
  • Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
  • History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
  • History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
  • Personal history of thromboembolic events
  • Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
  • Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
  • Blood donation (1 unit or more) within 3 months prior to randomization.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkeltdose
Eksperimentell: SC Dose
Single SC dose or matching placebo
Single ascending IV dose
Enkeltdose

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant laboratory assessment abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant Vital sign abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant physical examination abnormalities
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for tetanus
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for diphtheria
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for pneumococcus
Tidsramme: Up to week 12
Up to week 12

Sekundære resultatmål

Resultatmål
Tidsramme
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Tidsramme: Up to week 12
Up to week 12
Number of participants with positive serum anti-BIIB063 antibodies
Tidsramme: Up to week 12
Up to week 12
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Tidsramme: Up to 12 weeks
Up to 12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. september 2015

Primær fullføring (Faktiske)

1. juni 2016

Studiet fullført (Faktiske)

1. juni 2016

Datoer for studieregistrering

Først innsendt

27. august 2015

Først innsendt som oppfylte QC-kriteriene

17. september 2015

Først lagt ut (Anslag)

21. september 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. april 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. april 2017

Sist bekreftet

1. april 2017

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 234HV101
  • 2015-001283-18 (EudraCT-nummer)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere